|
1
|
Stinchcombe TE, Lee CB and Socinski MA:
Current aproaches to advanced-stage non-small-cel lung cancer:
First-line therapy in patients with a good functional status. Clin
Lung Cancer. 7 Suppl 4:S111–S117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugiura H, Yamada K, Sugiura T, Hida T and
Mitsudomi T: Predictors of survival in patients with bone
metastasis of lung cancer. Clin Orthop Relat Res. 466:729–736.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Botteman M, Barghout V, Stephens J, Hay J,
Brandman J and Aapro M: Cost effectiveness of bisphosphonates in
the management of breast cancer patients with bone metastases. Ann
Oncol. 17:1072–1082. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsuya A, Kurata T, Tamura K and Fukuoka M:
Skeletal metastases in non-small cell lung cancer: A retrospective
study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosen LS, Gordon D, Tchekmedyian S,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng
M, Urbanowitz G, et al: Zoledronic acid versus placebo in the
treatment of skeletal metastases in patients with lung cancer and
other solid tumors: A phase III, double blind, randomized trial-the
zoledoronic acid lung cancer and other solid tumors study group. J
Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosen LS, Gordon D, Tchekmedyian NS,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng
M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic
acid in the treatment of skeletal metastases in patients with
nonsmall cell lung carcinoma and other solid tumors: A randomized,
phase III, double blind, placebo-controlled trial. Cancer.
100:2613–2221. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishiwata T, Hirose T, Hirama M, Miura K,
Iwakami S, Tominaga S, Adachi M and Takahashi K: A feasibility
study of zoledronic acid combined with carboplatin/nedaplatin plus
paclitaxel in patients with non-small cell lung cancer with bone
metastases. Tumori. 97:568–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Addeo R, Nocera V, Faiola V, Vincenzi B,
Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, et
al: Management of pain in elderly patients receiving infusion of
zoledronic acid for bone metastasis: A single-institution report.
Support Care Cancer. 16:209–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Facchini G, Caraglier M, Santini D, Nasti
G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G,
et al: The clinical response on bone metastasis from breast and
lung cancer during treatment with zoledronic acid is inversely
correlated to skeletal related events (SRE). J Exp Clin Cancer Res.
26:307–312. 2007.PubMed/NCBI
|
|
11
|
Katakami N, Kunikane H, Takeda K, Takayama
K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, et al:
Prospective study on the incidence of bone metastasis (BM) and
skeletal-related events (SREs) in patients (pts) with stage IIIB
and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 9:231–238. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchiya A, Ikeda S, Ikegami N, Nishimura
S, Sakai I, Fukuda T, Hamashima C, Hisashige A and Tamura M:
Estimating an EQ-5D population value set: The case of Japan. Health
Econ. 11:341–353. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS,
Kaplan E and Bonomi P: Reliability and validity of the functional
assessment of cancer therapy-lung (FACT-L) quality of life
instrument. Lung Cancer. 12:199–220. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahoney FI and Barthel DW: Functional
evaluation; the Barthel Index. Md State Med J. 14:61–65.
1965.PubMed/NCBI
|
|
15
|
Kretzschmar A, Wiegel T, AI-Batran SE,
Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt
K, Haus U, et al: Rapid and sustained influence of intravenous
zoledronic acid on course of pain and analgesics consumption in
patients with cancer with bone metastases: A multicenter open-label
study over 1 year. Support Cancer Ther. 4:203–210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mystakidou K, Katsouda E, Parpa E,
Kouskouni E, Chondros C, Tsiatas ML, Galanos A and Vlahos L: A
prospective randomized controlled clinical trial of zoledronic acid
for bone metastases. Am J Hosp Palliat Care. 23:41–50. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chow E and Bottomley A: Understanding the
EORTC QLQ-BM22, the module for patients with bone metastases.
Expert Rev Pharmacoecon Outcomes Res. 9:461–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koizumi M, Yoshimoto M, Kasumi F, Iwase T
and Ogata E: Post-operative breast cancer patients diagnosed with
skeletal metastasis without bone pain had fewer skeletal-related
events and deaths than these with bone pain. BMC Cancer.
10:4232010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bezjak A, Lee CW, Ding K, Brundage M,
Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour
L and Shepherd FA: Quality-of-life outcomes for adjuvant
chemotherapy in early-stage non-small-cell lung cancer: Result from
a randomized trial, JBR. 10. J Clin Oncol. 26:5052–5059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mills M, Murray LJ, Johnston BT, Cardwell
C and Donnelly M: Does a patient-held quality-of-life diary benefit
patients with inoperable lung cancer? J Clin Oncol. 27:70–77. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Efficace F, Bottomley A, Smit EF, Lianes
P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B,
et al: Is a patient's self-reported health-related quality of life
a prognostic factor for survival in non-small-cell lung cancer
patients? A multivariate analysis of prognostic factors of EORTC
study 08975. Ann Oncol. 17:1698–1704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Belani CP, Brodowicz T, Ciuleanu TE,
Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A,
Ramlau R, et al: Quality of life in patients with advanced
non-small-cell lung cancer given maintenance treatment with
pemetrexed versus placebo (H3H-MC-JMEN): Result from a randomised,
double-blind, phase 3 study. Lancet Oncol. 13:292–299. 2012.
View Article : Google Scholar : PubMed/NCBI
|
